Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

Inclusion Criteria: * Treatment experienced subjects defined as subjects with 1 prior dose of same intravitreal anti-VEGF therapy given within the past 8 weeks for neovascular age-related macular degeneration (NVAMD) in the study eye. There must be \< 0 letters of improvement in Snellen (not ETDRS Snellen equivalent) visual acuity since the start of anti-VEGF treatment. * Presence of subfoveal active choroidal neovascularization (CNV) Exclusion Criteria: * Intravitreal treatment in the study eye prior to the Day 1 visit, regardless of indication, with the exception of the 1 prior anti-VEGF injections. * Presence of other causes of choroidal neovascularization, including pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, and multifocal choroiditis. * Non-pharmacologic treatment (intraocular surgery or thermal laser) within three months of trial entry. * Prior thermal laser in the macular region, regardless of indication. * Ocular or periocular infection in the past twelve weeks. * History of any of the following conditions or procedures in the study eye: rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery, glaucoma drainage device, or corneal transplant. * Previous therapeutic radiation in the region of the study eye. * Evidence of diabetic retinopathy